Eli Marsden on Muck Rack

Eli Marsden

Covers:  GLP-1 weight-loss medications, semaglutide, tirzepatide, telehealth providers, compounded GLP-1, obesity pharmacotherapy, insurance and prior authorization

Get in touch with Eli

Contact Eli, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Eli Marsden’s Biography

Read Full Bio →

Eli Marsden is the founding editor of Weight Loss Rankings, an independent, research-driven review site covering GLP-1 weight-loss medications, telehealth providers, and the clinical evidence behind semaglutide and tirzepatide. Eli writes plain-English, citation-backed guides that help readers compare cash-pay GLP-1 options, understand insurance and prior-authorization coverage, and separate marketing claims from trial data.

Eli Marsden’s Journalist Portfolio

Cheapest GLP-1 Without Insurance in 2026: Buyer's Guide

Cheapest GLP-1 Without Insurance in 2026: Buyer's Guide

The cheapest legitimate GLP-1 in 2026 is Foundayo (oral orforglipron) or Wegovy oral pill at $149/month.

View article →
Compounded Semaglutide vs Wegovy: Bioequivalence Evidence Review

Compounded Semaglutide vs Wegovy: Bioequivalence Evidence Review

No FDA bioequivalence study exists between compounded semaglutide and Wegovy. The 2022-2025 shortage carveout…

View article →
Compounded Tirzepatide vs Compounded Semaglutide: Differences, Efficacy, Storage & Stability

Compounded Tirzepatide vs Compounded Semaglutide: Differences, Efficacy, Storage & Stability

Side-by-side comparison of compounded tirzepatide vs compounded semaglutide: molecule differences (GLP-1 only…

View article →
How Compounded GLP-1 Prices Moved Over the Last 16 Months: Provider-by-Provider Trajectories

How Compounded GLP-1 Prices Moved Over the Last 16 Months: Provider-by-Provider Trajectories

We tracked monthly cash prices for compounded semaglutide across the largest telehealth providers from Januar…

View article →
Foundayo (Orforglipron) Side Effects: Comprehensive Evidence Review

Foundayo (Orforglipron) Side Effects: Comprehensive Evidence Review

Comprehensive Foundayo (orforglipron) adverse-event review across the three pivotal trials: ATTAIN-1 in obesi…

View article →

Articles

Foundayo (Orforglipron) Side Effects: Comprehensive Evidence Review

|
By Eli Marsden
| weightlossrankings.org
The honest answer: Foundayo (orforglipron) is a once-daily oral small-molecule GLP-1 receptor agonist, FDA-approved April 1, 2026 for chronic weight management.
Open in Who Shared Issue with article?

Compounded Semaglutide vs Wegovy: Bioequivalence Evidence Review

|
By Eli Marsden
Not BECompounded vs Wegovy bioequivalence Compounded semaglutide vs Wegovy bioequivalence evidence: no FDA bioequivalence study exists, shortage window closed February 2025, FDA enforcement now active The honest answer: Compounded semaglutide is not FDA-tested for bioequivalence to Wegovy. No such study has ever been required, run, or published.
Open in Who Shared Issue with article?

Cheapest GLP-1 Without Insurance in 2026: Buyer's Guide

|
By Eli Marsden
$149/mocheapest legitimate FDA-approved GLP-1 in 2026 Cheapest GLP-1 without insurance 2026 buyer’s guide — Foundayo oral and Wegovy oral pill at $149 per month, LillyDirect Self Pay Zepbound vials $299-$449 per month, NovoCare Wegovy pen $299 per month, compounded semaglutide $99-$300 per month with regulatory caveats Cash-pay GLP-1 pricing changed dramatically in late 2025 and early 2026.
Open in Who Shared Issue with article?
See all 5 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified